Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia

Hematology Journal

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Hallek, Michael ^a   Eichhorst, Barbara F ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chronic lymphocytic leukemia; combination chemotheraphy; Fludarabine

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; GRANULOCYTOPENIA; HUMAN; LEUKEMIA REMISSION; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMONIA; PUBLICATION; SEPSIS; THROMBOCYTOPENIA;

EID: 2942613823     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200388     Document Type: Article

References (44)

1. Keating M, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165-1171.
2. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-2884.
3. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-1757.
4. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44-49.
5. Zinzani PL, Lauria F, Rondelli D, Benfenati D, Raspadori D, Bocchia M et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur J Haematol 1993; 51: 93-97.
6. Montserrat E, Lopez-Lorenzo JL, Manso F, Martin A, Prieto E, Arias-Sampedro J et al. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia the Spanish group experience. Leuk Lymphoma 1996; 21: 467-472.
7. Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol 1997; 15: 458-465.
8. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319-2325.
9. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432-1438.
10. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 2836-2843.
11. Koehl U, Li L, Nowak B. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal. Proc Am Assoc Cancer Res 1997; 38: 2.
12. Gandhi V, Nowak B, Keating MJ, Plunkett W. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood 1989; 74: 2070-2075.
13. Avramis VI, Champagne J, Sato J, Krailo M, Ettinger LJ, Poplack DG et al. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res 1990; 50:7226-7231.
14. Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res 1996; 2: 653-658.
15. Santini V, D'Ippolito G, Bernabei PA, Zoccolante A, Ermini A, Rossi-Ferrini P. Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement. Leuk Res 1996; 20: 37-45.
16. Rayappa C, McCulloch EA. A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside. Leukemia 1993; 7: 992-999.
17. Yang L-Y, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 1995; 47: 1072-1079.
18. Zaffaroni N, Orlandi L, Gornati D, De Marco C, Vaglini M, Silvestrini R. Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines. Eur J Cancer 1996; 32A: 1766-1773.
19. Knauf WU, Kreuser ED, Pottgiesser E, Thiel E. In vitro and in vivo effectiveness of fludarabine in B-cell chronic lymphocytic leukemia (B-CLL). Ann Hematol 1992; 65: A80.
20. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
21. Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71-77.
22. Flinn IW, Jemiai Y, Bennett JM, Falkson CI, Flynn P, Pundaleeka S et al. Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia: ECOG 1997. Blood 2001; 98: 633a.
23. O'Brien S. Clinical challenges in chronic lymphocytic leukemia. Semin Hematol 1998; 35: 22-26.
24. O'Brien S, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414-1420.
25. Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol 2001; 114: 342-348.
26. Cazin B, Maloum K, Divine M, Lepretre S, Travade P, Delmer A et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 75 pts. Blood 2002; 100: 206a.
27. Eichhorst BF, Hopfinger G, Pasold R, Hensel M, Söling U, Siehl S et al. Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL): results of a phase III study (CLL4 protocol) of the German CLL Study Group (GCLLSG). Blood 2003; 102: 243a.
28. Hallek M, Wilhelm M, Emmerich B, Dohner H, Fostitsch HP, Sezer O et al. Fludarabine plus cyclophosphamide (FC) and dose-intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL): results of two phase II studies (CLL2-protocol) of the German CLL Study Group (GCLLSG). Blood 1999; 94: 313a.
29. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976-984.
30. Schmitt B, Franke A, Burkhard O, Schlag R, Hopfinger G, Stauch M et al. Fludarabine, mitoxantrone and cyclophosphamide combination therapy in relapsed chronic lymphocytic leukemia (CLL) with or without G-CSF: results of the first interim analysis of a phase III study of the German CLL Study Group (GCLLSG). Blood 2002; 100: 364.
31. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-1700.
32. Weiss M, Spiess T, Berman E, Kempin S. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 1994; 8: 1290-1293.
33. Elias L, Stock-Novack D, Head DR, Grever MR, Weick JK, Chapman RA et al. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia 1993; 7: 361-365.
34. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR et al. Impact of therapy with chlorambucil, fLudarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001; 19: 3611-3621.
35. Rummel MJ, Kafer G, Pfreundschuh M, Jager E, Reinhardt U, Mitrou PS et al. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. Ann Oncol 1999; 10: 183-188.
36. Rummel MJ, Stilgenbauer S, Gamm H, Rost A, Doehner H, Hoelzer d et al. Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia (CLL) - preliminary results of a randomized phase-III multicenter study. Blood 2002; 100: 384a.
37. O'Brien S, Kantarjian H, Beran C, Robertson IE, Freireich E, Kornblau S et al. Fludarabine (FAMP) and mitoxantrone therapy in chronic lymphocytic-leukemia (CLL). Blood 1996; 88: 588a.
38. Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 1994; 34: 30-36.
39. Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma 1999; 36: 57-65.
40. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9: 943-945.
41. Mauro FR, Foa R, Meloni G, Gentile M, Giammartini E, Giannarelli D et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica 2002; 87: 926-933.
42. O'Brien S, Kantarjian H, Beran C, Koller C, Talpaz M, Lerner S et al. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997; 11: 1631-1635.
43. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559-566.
44. Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma 2002; 3: 26-35.